Stelios Kympouropoulos | f.MEP
European Parliament

Day 2 - Wednesday 29 October @ 09:00

Keynote Panel: Leveraging new technology for smarter decision-making in Rare Disease drug development and access

-What advancements have been made towards AI, RWE and scientific breakthroughs in rare diseases? e.g. Patient behaviour and trial recruitment, data collection, digital health, mRNA & other platforms, wearables devices etc.

-Are these technologies being used and do they add significant value to the healthcare ecosystem. E.g., to improve the diagnosis pathway, access to care, clinician workload and impact on healthcare system for rare diseases

-Are regulators, HTAs and payers supportive of these advancements, does it help with their decision-making process?

Moderator: Claire Skentelbery, Director General, EuropaBio

Christopher Rudolf, Founder & CEO, Volv Global

×

Christopher Rudolf / Keynote Panel: Leveraging new technology for smarter decision-making in Rare Disease drug development and access

Christopher Rudolf, Founder & CEO,
Volv Global

Christopher Rudolf is a seasoned technology entrepreneur and business advisor with over 30 years of experience, specialising in data science, AI, and medical informatics. As the founder and CEO of Volv Global SA, he leads the company's mission to transform healthcare through advanced machine...

CloseMore

Julian Isla, Director, Foundation 29

×

Julian Isla / Keynote Panel: Leveraging new technology for smarter decision-making in Rare Disease drug development and access

Julian Isla, Director,
Foundation 29

Julian Isla is a software engineer by training and works as a Resource Manager for the Artificial Intelligence group at Microsoft. He has 29 years of experience working for international IT companies, helping customers with digital transformation and leveraging the capacity of artificial...

CloseMore

Stelios Kympouropoulos, f.MEP, European Parliament

Mohit Jain, Vice President, Market Access, International Operations, IntraBio

Wim Goettsch, Special Advisor HTA & Professor for HTA of Pharmaceuticals, Zorginstituut

×

Wim Goettsch / Keynote Panel: Leveraging new technology for smarter decision-making in Rare Disease drug development and access

Wim Goettsch, Special Advisor HTA & Professor for HTA of Pharmaceuticals,
Zorginstituut

Wim Goettsch, PhD, is Special Advisor in Health Technology Assessment (HTA) at the Dutch National Health Care Institute (ZIN). In his position at ZIN, he is a Member of the EU HTAR Coordination Group and its subgroup on Joint Scientific Consultation (JSC). Between 2010 and 2013, he was the Deputy...

CloseMore

Michael Merchant, Scientific Adviser, National Institute for Health and Care Excellence

×

Michael Merchant / Keynote Panel: Leveraging new technology for smarter decision-making in Rare Disease drug development and access

Michael Merchant, Scientific Adviser,
National Institute for Health and Care Excellence

Dr Michael Merchant is a Scientific Adviser in the Data and Analytics team at NICE. He joined NICE in 2023, to work on Real World Evidence for Clinical Prediction Models and AI predictive technologies for diagnosis and prognosis. This work is in review and will form part of the NICE Real World...

CloseMore